Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the quick ratio (acid-test) high or low?
The quick ratio (acid-test) of 11.59 is 23% below its 3-year average of 14.96, around the middle of its 3-year range (0.00–36.01).
As of the fiscal period ended Tuesday, June 30, 2026. 27.53% below its 12-month average of 15.99.
Reported quarterly quick ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 11.59.
QUICK RATIO (ACID-TEST)
11.59
QUICK RATIO (ACID-TEST) AVG TTM
15.99
QUICK RATIO (ACID-TEST) AVG 3Y
16.12
QUICK RATIO (ACID-TEST) AVG 5Y
N/A
QUICK RATIO (ACID-TEST) AVG 10Y
N/A
QUICK RATIO (ACID-TEST) AVG 15Y
N/A
QUICK RATIO (ACID-TEST) AVG 20Y
N/A
CURRENT VS TTM AVG
-27.53%
CURRENT VS 3Y AVG
-28.09%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
2.79
median of 388 covered companies
CURRENT VS SECTOR MEDIAN
+314.62%
vs the sector median at left
Bicara Therapeutics Inc. Common Stock
Market Cap
$1.14B
Quick Ratio (Acid-Test)
11.59
TTM Avg
15.99
3Y Avg
16.12
5Y Avg
N/A
Market Cap
$1.12B
Quick Ratio (Acid-Test)
5.85
TTM Avg
6.12
3Y Avg
6.56
5Y Avg
10.14
Market Cap
$1.12B
Quick Ratio (Acid-Test)
1.71
TTM Avg
2.54
3Y Avg
2.42
5Y Avg
2.25
Market Cap
$1.16B
Quick Ratio (Acid-Test)
1.38
TTM Avg
3.96
3Y Avg
6.78
5Y Avg
9.79
Market Cap
$1.20B
Quick Ratio (Acid-Test)
33.10
TTM Avg
10.19
3Y Avg
10.19
5Y Avg
10.19
Market Cap
$1.21B
Quick Ratio (Acid-Test)
15.25
TTM Avg
18.40
3Y Avg
18.04
5Y Avg
16.30
Market Cap
$1.05B
Quick Ratio (Acid-Test)
0.81
TTM Avg
2.16
3Y Avg
2.71
5Y Avg
2.89
Market Cap
$1.24B
Quick Ratio (Acid-Test)
19.73
TTM Avg
13.53
3Y Avg
9.78
5Y Avg
15.63
Market Cap
$989.05M
Quick Ratio (Acid-Test)
16.33
TTM Avg
11.68
3Y Avg
16.13
5Y Avg
16.13
| NAME | MARKET CAP | QUICK RATIO (ACID-TEST) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Bicara Therapeutics Inc. Common Stock (BCAX) | $1.14B | 11.59 | 15.99 | 16.12 | N/A |
| Castle Biosciences, Inc. (CSTL)vs › | $1.12B | 5.85 | 6.12 | 6.56 | 10.14 |
| Amphastar Pharmaceuticals, Inc. (AMPH)vs › | $1.12B | 1.71 | 2.54 | 2.42 | 2.25 |
| GoodRx Holdings, Inc. (GDRX)vs › | $1.16B | 1.38 | 3.96 | 6.78 | 9.79 |
| Avalyn Pharma Inc. Common Stock (AVLN)vs › | $1.20B | 33.10 | 10.19 | 10.19 | 10.19 |
| Cronos Group Inc. (CRON)vs › | $1.21B | 15.25 | 18.40 | 18.04 | 16.30 |
| Teladoc Health, Inc. (TDOC)vs › | $1.05B | 0.81 | 2.16 | 2.71 | 2.89 |
| Damora Therapeutics, Inc. (DMRA)vs › | $1.24B | 19.73 | 13.53 | 9.78 | 15.63 |
| Aktis Oncology, Inc. (AKTS)vs › | $989.05M | 16.33 | 11.68 | 16.13 | 16.13 |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $985.79M | 8.42 | 11.89 | 15.48 | 17.00 |
Quick Ratio
11.59
Excludes inventory
Current Ratio
11.59
Includes inventory
Quick Ratio = (Current Assets − Inventory) / Current Liabilities
The quick ratio is a stricter liquidity measure that excludes inventory, showing the ability to meet short-term obligations with the most liquid assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | QUICK RATIO (ACID-TEST) |
|---|---|
| 2026-06-30 | 11.59 |
| 2026-03-31 | 13.85 |
| 2025-12-31 | 14.58 |
| 2025-09-30 | 14.14 |
| 2025-06-30 | 25.80 |
| 2025-03-31 | 24.62 |
| 2024-12-31 | 27.93 |
| 2024-09-30 | 36.01 |
| 2024-06-30 | 12.83 |
| 2024-03-31 | 12.83 |
| 2023-12-31 | 15.32 |
| 2023-09-30 | 0.00 |
| 2023-06-30 | 0.00 |
| 2023-03-31 | 0.00 |
